Preparation method of lactobacillus paracasei for continuously and stably expressing GLP-1 based on endogenous CRISPR-Cas system
By applying the endogenous CRISPR-Cas9 system in Lactobacillus paracasei, the GLP-1 gene is integrated into the bacteria's chromosomes, solving the problem of frequent injection of existing GLP-1 administration methods, achieving continuous and stable expression and efficient administration of GLP-1, significantly improving patients' compliance and quality of life.
CN119709739APending Publication Date: 2025-03-28INST OF AGRO FOOD SCI & TECH CHINESE ACADEMY OF AGRI SCI
1 Cites 0 Cited by
Patent Information
- Application Number
- CN202411628521.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-14
- Publication Date
- 2025-03-28
AI Technical Summary
Technical Problem
The existing GLP-1 administration methods require frequent injections, resulting in low compliance and unstable treatment effects, and the inability to effectively control blood sugar levels in the long run.
Method used
Lactobacillus paracasei based on the endogenous CRISPR-Cas9 system was used to achieve its sustained and stable expression by directly integrating the GLP-1 gene into the chromosome of the bacteria.
Benefits of technology
This method not only ensures the stable and continuous expression of GLP-1, but also utilizes the natural gastrointestinal colonization ability of Lactobacillus paracasei, improves the bioavailability and efficacy of treatment, and significantly improves the patient's compliance and quality of life.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates to the technical field of gene engineering, in particular to a preparation method of lactobacillus paracasei capable of continuously and stably expressing GLP-1 based on an endogenous CRISPR-Cas system. According to the present invention, the GLP-1 gene is directly integrated into the chromosome of the lactobacillus paracasei by using the CRISPR-Cas9 system of the lactobacillus paracasei; the method not only ensures the stable and continuous expression of the GLP-1, but also utilizes the natural gastrointestinal tract colonization ability of the lactobacillus paracasei, and is beneficial to improving the bioavailability and curative effect of treatment. According to the invention, an oral GLP-1 delivery system based on probiotics is realized, the research and development of the system represent the reform progress of diabetes treatment, and GLP-1 in an injection form is possibly replaced, so that the treatment scheme is thoroughly changed, the outcome of a patient is improved, the compliance and life quality of the patient are remarkably improved, and the system has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art